Friday, May 9, 2014

Prima BioMed's CVac Granted Fast Track Designation by FDA (NEWS)

Prima BioMed  is pleased to announce today that the United States Food and Drug Administration granted Fast Track Designation to the CVac clinical development program at Prima. This program is intended to improve overall survival in patients with relapsed platinum-sensitive epithelial ovarian cancer who enter a second complete remission. Prima will work closely with the FDA in accelerating its development program for CVac to potentially bring this treatment option to patients in the U.S.  Here is the full PDF on Prima's website.